An AI native diagnostics platform is building modular lab infrastructure for emerging markets, combining edge hardware, imaging AI and cloud software to deliver affordable, high accuracy cancer and molecular tests.
What the company does
- Offers an integrated “lab platform as a service” built in house: a Jetson powered digital microscopy system for 40x whole slide imaging, an AI engine for cervical cancer screening trained on 10k+ images with ~99.6% sensitivity, and a secure hybrid cloud for real time data and reporting.* Automates the full workflow on device—image capture, stitching, compression, AI inference and visualisation—reducing dependence on constant connectivity and making advanced pathology viable in resource constrained and rural settings.
Traction and technology
- Has processed over 20,000 cases in two years across South Asia and Europe, with deployments for organisations such as Rotary, UNESCO, NHS linked partners and leading Indian hospitals and NGOs.
- Demonstrates strong economics: significant savings in hard infrastructure, low variable and logistics costs, and capacity building for local pathologists, while delivering accuracy close to gold standard molecular tests at materially lower cost.
- Competes in the “ideal zone” of high clinical sensitivity and cost efficiency versus legacy visual inspections, PAP smears and rapid tests, positioning itself as an enabling platform for global health equity.